Overview
This study evaluates the use of specialized magnetic resonance imaging (MRI) techniques including magnetic resonance (MR) perfusion and 2-hydroxyglutarate (2HG) spectroscopy in the surgical treatment of gliomas.
Cohort 1 participants will undergo an MR perfusion scan or 2-HG spectroscopy prior to surgery and intra-operatively.
Cohort 2 participants will only undergo standard of care imaging and tumor acquisition. Participant participation will end at the completion of surgery and will be transitioned to standard of care follow-up.
Eligibility
Inclusion Criteria:
- Age ≥ 18 years
- Suspected glioma (grade II, III, or IV)
- Preoperative MR perfusion (enhancing tumors)
- Preoperative MR 2-HG spectroscopy (nonenhancing tumors)Patient indicated for surgical resection, standard radiation, and standard chemotherapy as a standard of care
- Karnofsky performance status ≥ 60
- Life expectancy > 12 weeks
- Cohort 1: Ability to comply with study and follow-up procedures
- Cohort 2: Ability to comply with study procedures
Exclusion Criteria:
- Prior diagnosis of intracranial glioma
- Other malignancy with expected need for systemic therapy within 3 years
- Inability to have 6000 grays of radiation to the brain
- Need for urgent palliative intervention for primary disease (e.g., impending herniation)
- Evidence of bleeding diathesis or coagulopathy
- History of intracerebral abscess within 6 months prior to Day 0
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study
- Pregnant females
- Subjects unable to undergo an MRI with contrast